GRTS News and Press, Gritstone Oncology Inc. From 09/12/22

-- SLATE vaccines (version 1 and SLATE-KRAS) demonstrate early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) -- -- Molecular response, as measu...

EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking ...

Gritstone bio ( NASDAQ: GRTS ) slipped ~14% in the pre-market trading Monday after Goldman Sachs downgraded the immunotherapy developer to Sell from Neutral, citing concerns over its liquidity position. The analyst Corinne Jenkins thinks that GRTS' current cash positio...

Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...

The shares of Gritstone bio, Inc. ( NASDAQ: GRTS ) climbed ~35% to reach the highest level since February on Tuesday after the clinical-stage biotech announced the publication of interim data from its Phase 1/2 trial for GRANITE, an individualized vaccine candidate for sol...

-- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to molecular responses in advanced colorectal cancer (CRC) patients and associated with...

EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced the appointment of Lawrence “Larry” Corey, M.D., to its Board of Direc...

Gritstone Oncology press release ( NASDAQ: GRTS ): Q2 GAAP EPS of -$0.34 beats by $0.07 . Revenue of $5.47M (+92.6% Y/Y) beats by $2.28M . For further details see: Gritstone Oncology GAAP EPS of -$0.34 beats by $0.07, revenue of $5.47M beats by $2.28M

-- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong ...

EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted three employees nonqualifie...